Generic Medicine Info
Indications and Dosage
Acute uncomplicated falciparum malaria
Adult: 80 mg daily, to be taken with lumefantrine 480 mg daily. Doses to be taken at diagnosis and repeated after 8, 24, 36, 48 and 60 hr. Total doses: 6.
Child: Daily doses based on body wt: 5-14 kg: 20 mg with lumefantrine 120 mg; 15-24 kg: 40 mg with lumefantrine 240 mg; 25-34 kg: 60 mg with lumefantrine 360 mg and >34 kg: 80 mg with lumefantrine 480 mg. Doses to be taken at diagnosis and repeated after 8, 24, 36, 48 and 60 hr. Total doses: 6.
Should be taken with food.
Special Precautions
Pregnancy and lactation. Avoid concomitant use of drugs known to prolong QT interval or monitor such patients.
Adverse Reactions
Mild GI disturbance, dizziness, tinnitus, reduction in reticulocyte and leucocyte counts, nausea, vomiting, abdominal pain, bradycardia, 1st-degree heart block, transient increase in serum transaminases.
Drug Interactions
Artemether causes QT prolongation in some patients. Thus concomitant use of erythromycin, terfenadine, procainamide, quinidine, disopyramide, amiodarone, bretylium, bepridil, sotalol, astemizole, probucol, tricyclic antidepressants, phenothiazines may be avoided.
Description: Artemether is a potent and rapidly acting blood schizontocide, which is highly efficacious in treating chloroquine-resistant falciparum malaria, and complicated falciparum malaria including cerebral malaria. Its quick onset of effect and high efficacy in bringing down the parasite load are the properties which make this drug a suitable therapeutic option against falciparum infection.
Metabolism: Rapidly hydrolysed to the active metabolite dihydroartemisinin.
Excretion: Elimination half-life: about 4-11 hr after IM or oral admin.
Store below 30°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Artemether from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in